Deng Jie, Cai Yun, Liao Juan, Hou Ruining, Cui Jie
Department of Gynaecology, Baoji Traditional Chinese Medicine Hospital No. 58 Administrative Avenue, Jintai District, Baoji 721001, Shaanxi, China.
Department of Radiotherapy III, Shaanxi Provincial Cancer Hospital No. 309 Yanta West Road, Yanta District, Xi'an 710061, Shaanxi, China.
Am J Transl Res. 2025 Apr 15;17(4):2484-2499. doi: 10.62347/OMOR8605. eCollection 2025.
To investigate the effects of combining nedaplatin with paclitaxel liposomes or docetaxel on survival rates and biomarkers in patients with recurrent ovarian cancer (ROC).
A retrospective analysis was carried out on the clinical data of 238 ROC patients treated at Baoji Traditional Chinese Medicine Hospital between February 2018 and February 2022. The patients were divided into a control group (n=103), which received nedaplatin combined with paclitaxel liposomes, and an observation group (n=135), receiving nedaplatin combined with docetaxel. The treatment efficacy, adverse reactions, tumor biomarkers (CA125, CEA, HE4, and AFP), and inflammatory markers (TNF-α, IL-6) before and after treatment were compared between the two groups. Patients were followed up for 2 years to observe progression-free survival (PFS), and Kaplan-Meier survival curves were plotted and Logrank tests were performed to evaluate the 2-year PFS differences.
There were no significant differences in overall clinical efficacy or remission rates between the two groups post-treatment (both P>0.05). Both groups showed significant reductions in tumor biomarkers and inflammatory markers after treatment compared with pre-treatment levels (all P<0.05), and the differences between the groups after treatment were not significant (all P>0.05). The incidence of adverse reactions was also similar between the groups (P>0.05). Multivariate Cox regression analysis identified the treatment regimen (P<0.001), FIGO stage (P=0.005), maximum diameter of recurrent lesions (P=0.001), number of recurrent lesions (P<0.001), post-treatment CA125 (P<0.001), and post-treatment HE4 (P<0.001) as independent prognostic factors for PFS.
The combination of nedaplatin with paclitaxel liposomes or docetaxel demonstrated comparable efficacy in ROC patients, effectively reducing tumor and inflammatory markers without increasing adverse reactions. Importantly, the combination of nedaplatin and docetaxel significantly improved PFS.
探讨奈达铂联合紫杉醇脂质体或多西他赛对复发性卵巢癌（ROC）患者生存率及生物标志物的影响。
对2018年2月至2022年2月在宝鸡市中医医院接受治疗的238例ROC患者的临床资料进行回顾性分析。将患者分为对照组（n = 103），接受奈达铂联合紫杉醇脂质体治疗；观察组（n = 135），接受奈达铂联合多西他赛治疗。比较两组治疗前后的治疗效果、不良反应、肿瘤生物标志物（CA125、CEA、HE4和AFP）及炎症标志物（TNF-α、IL-6）。对患者进行2年随访，观察无进展生存期（PFS），绘制Kaplan-Meier生存曲线并进行Logrank检验，以评估两组2年PFS的差异。
两组治疗后总体临床疗效和缓解率差异均无统计学意义（均P>0.05）。与治疗前水平相比，两组治疗后肿瘤生物标志物和炎症标志物均显著降低（均P<0.05），且治疗后两组间差异无统计学意义（均P>0.05）。两组不良反应发生率也相似（P>0.05）。多因素Cox回归分析确定治疗方案（P<0.001）、国际妇产科联盟（FIGO）分期（P = 0.005）、复发病变最大直径（P = 0.001）、复发病变数量（P<0.001）、治疗后CA125（P<0.001）和治疗后HE4（P<0.001）为PFS的独立预后因素。
奈达铂联合紫杉醇脂质体或多西他赛在ROC患者中显示出相当的疗效，能有效降低肿瘤和炎症标志物水平，且不增加不良反应。重要的是，奈达铂联合多西他赛显著改善了PFS。
